GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.

British drug maker GlaxoSmithKline (GSK) is voluntarily recalling 593,000 Ventolin asthma inhalers from hospitals, pharmacy, retailers, and wholesalers in the U.S. due to an issue that may cause the inhalers to deliver a lower than intended dose of the medication.

The company had been receiving complaints about a leak of the propellant that delivers the medication, Reuters said. The recall impacts three lots of the inhalers that were manufactured at the company's GSK plant in Zebulon, North Carolina.

Shares of GSK were up slightly in pre-market trading Wednesday. 

If you liked this article you might like

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Mylan Badly Needs Help from FDA to Escape its Woes and Deliver These Key Drugs